Australia seems poised to welcome innovative therapy for obesity: Retatrutide. The dual compound – targeting on both GLP-1 and GIP receptors – demonstrates significant efficacy in global studies, pointing to considerable reductions in weight. While availability remains with the Therapeutic Goods Administration (TGA), many Australians battling b